Interestingly, a small retrospective analysis of non-Hodgkin’s lymphoma participants demonstrated a reduction in FDG uptake in the carotid arteries after 9 weeks of Magrolimab treatment, suggesting that CD47 inhibition might reduce vascular inflammation [66]. This evidence concerns the gene CD47 and non-Hodgkin lymphoma.